Clinical Trial: PITUItary Carcinoma or Aggressive Tumors REgistry -Lyon

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Observational

Official Title: PITUItary Carcinomas or Aggressive Tumors REgistry: Monocentric Study Form a Cohort of Patient Operated on for Pituitary Tumors in University Hospital of Lyon (France)

Brief Summary: The purpose of this study is to observe predictors of pituitary tumor recurrence and markers of persistent disease activity through computerized collection of comprehensive demographic, therapeutic, pathologic and outcome information on patients harboring pituitary mass lesions of all types.

Detailed Summary:
Sponsor: Hospices Civils de Lyon

Current Primary Outcome: Progression free survival after pituitary surgery according to the clinicopathological classification (HYPOPRONOS) [ Time Frame: up to 10 years (postoperatively) ]

Clinical, biochemical et imaging evaluation of a cohort of patient operated in the referral center for pituitary tumor.

Identification of recurrence or progression an analysis of the clinicopathological classification.

Evaluation of the different therapeutic strategies (med, surgery, chemotherapies, radiation therapy) to prevent recurrence or tumor progression.



Original Primary Outcome: Same as current

Current Secondary Outcome:

  • Correlation between percentage of SSTR expression of the pituitary tumor and somatostatine analogs efficacy. [ Time Frame: 2007-2020 ]

    Analysis of the expression of SST receptors in GH, PRL and ACTH secreting pituitary tumors: SSTR expression accessed by immunohistochemistry of the pituitary tumor.

    Evaluation of the response to somatostatine analogs: somatostatine analogs efficacy evaluated by normalization of hormone hypersecretion in ACTH, GH and PRL secreting pituitary tumor.

  • Correlation between percentage of MGMT expression of the pituitary tumor and tumor response to temozolomide. [ Time Frame: 2007-2020 ]
    Evaluation of MGMT expression (accessed by immunohistochemistry of the pituitary tumor) and response to temozolomide treatment (evaluated according to RECIST criteria) for patient presenting multirecurrent tumors resistant to conventional treatment.


Original Secondary Outcome: Same as current

Information By: Hospices Civils de Lyon

Dates:
Date Received: July 27, 2016
Date Started: February 2007
Date Completion: December 2020
Last Updated: July 29, 2016
Last Verified: July 2016